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Summary box
 Ź Global health research has typically focused on 
single diseases, and most economic evaluation re-
search has analysed technical health interventions 
to identify ‘best buys’.
 Ź New approaches in the conduct of economic evalu-
ations are needed to help policymakers in choosing 
what may be good value (ie, greater health, distribu-
tion of health, or inancial risk protection) for money 
(ie, per budget expenditure) investments for health 
system strengthening (HSS).
 Ź Economic evaluations of HSS interventions will re-
quire developing new analytic models of health 
systems which recognise the dynamic connections 
between the different components of the health 
system.
 Ź We describe priority health system modelling re-
search areas to conduct economic evaluation of HSS 
interventions and ultimately identify good value for 
money investments in HSS.
AbSTrACT
Global health research has typically focused on single 
diseases, and most economic evaluation research to 
date has analysed technical health interventions to 
identify ‘best buys’. New approaches in the conduct of 
economic evaluations are needed to help policymakers 
in choosing what may be good value (ie, greater health, 
distribution of health, or inancial risk protection) for 
money (ie, per budget expenditure) investments for 
health system strengthening (HSS) that tend to be 
programmatic. We posit that these economic evaluations 
of HSS interventions will require developing new analytic 
models of health systems which recognise the dynamic 
connections between the different components of the 
health system, characterise the type and interlinks of the 
system’s delivery platforms; and acknowledge the multiple 
constraints both within and outside the health sector 
which limit the system’s capacity to eficiently attain its 
objectives. We describe priority health system modelling 
research areas to conduct economic evaluation of HSS 
interventions and ultimately identify good value for money 
investments in HSS.
InTroduCTIon
Non-communicable diseases (NCDs), which 
often manifest with multiple conditions 
within the same patient, expose some of the 
inadequacies of health systems unprepared 
for the rapid epidemiological transition from 
communicable diseases to NCDs.1 2 Govern-
ments, international organisations and 
donors worldwide are concerned about 
rising costs of healthcare, coupled with 
inadequate performance of national health 
systems. Moreover, the rise in NCD burden 
has driven cost increases as more expensive 
therapies are needed for longer durations 
of treatment. Hence, many policymakers are 
concerned about improving efficiency and 
effectiveness of health systems.
Contrary to these looming trends, 
however, global health research has typi-
cally focused on single diseases, on vertical 
programmes in isolation and on single tech-
nical interventions (eg, introduction of 
new technologies like vaccines or drugs).3 
As a case in point, most economic evalua-
tions to date, including cost-effectiveness 
analysis research that explores both tech-
nical and allocative efficiency, have anal-
ysed single health interventions and thus 
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Figure 1 Description of the health system elements and 
policy levers which are subject to dynamic interactions and 
constraints and are amenable to health system modelling. 
Adapted from Roberts, Hsiao, Berman and Reich (2008).
operationalised the computation of total health gains 
(eg, total deaths averted or disability-adjusted life years 
averted) per total expenditure on specific interventions 
to identify ‘best buys’.4
New approaches in the conduct of economic evalu-
ations are needed to help policymakers choose what 
may be good value (ie, greater health, distribution of 
health, or financial risk protection) for money (ie, per 
budget expenditure) investments for health system 
strengthening (HSS) that tend to be programmatic 
rather than single technical interventions. As a result, 
HSS interventions are more difficult to evaluate. HSS 
interventions that warrant evaluation include, for 
example, workforce training and deployment, pharma-
ceutical procurement and supply chain management, 
organisational management, cross-sectoral coordina-
tion and community-based convening. We posit that 
these new approaches must first consider system-wide 
delivery platforms (eg, district public health depart-
ments, health posts, community health workers, 
clinics) and operational elements (eg, community 
health boards, data information systems, supply chains) 
as units of analysis, in place of disease-focused inter-
ventions, to improve one particular platform (tech-
nical efficiency) or ration across platforms (allocative 
efficiency). Second, they should capture the dynamic 
interactions between the main interdependent compo-
nents of health systems, specifically financing, delivery, 
individual behaviour and community decision-making, 
accounting for feedbacks, adaptations and synergies. 
Third, they have to maintain, as central outcomes of 
interest, the major objectives—what we call ‘value’ in 
this paper—of health systems commonly agreed on,5–7 
notably: improving health and its distribution at the 
level of the population, providing financial risk protec-
tion efficiently (accounting for budget constraints),8 
and increasing the satisfaction of citizens, while poten-
tially acknowledging the positive implications that a 
healthier population may have on healthcare and the 
broader economy.9 Fourth, they should clearly articu-
late the comparators and counterfactuals pertaining to 
HSS interventions: whether an HSS intervention (eg, 
workforce training) is compared with another HSS 
intervention (eg, improving the drug supply chain) 
or with the status quo. Last, evaluation of multiple 
outcomes (eg, health, distribution of health, financial 
risk protection) raises the question of how to weigh each 
of these outcomes against one another and whether to 
produce an aggregated summary value or to maintain a 
dashboard of outcomes.
Collectively, these considerations imply that economic 
evaluations of HSS interventions will require devel-
oping new analytic models of health systems which: 
(1) acknowledge the dynamic connections between 
the different components of the health system and the 
policy levers acting on them, as well as characterise 
the type and interlinks of the system’s delivery plat-
forms—that is, quantify the dynamic interactions between 
major health system components and (2) recognise the 
multiple constraints both within and outside the health 
sector which limit the system’s capacity to efficiently 
attain its objectives—that is, incorporate the constraints 
limiting the delivery of health to populations.
In illustrating such priority health system modelling 
(HSM) research areas for conducting economic eval-
uations of HSS interventions, we keep in mind the 
following major analytical question: how to identify 
good value (ie, greater health, distribution of health, 
or financial risk protection) for money (ie, per budget 
expenditure) investments in HSS?
PrIorITy HSM reSeArCH AreAS
Quantifying the dynamic interactions between major health 
system components
Beyond technical interventions, the WHO has defined 
six components of health systems10 and the World 
Bank’s flagship course on health system strength-
ening and sustainable financing has highlighted five 
control knobs or policy levers (financing, payment, 
organisation, regulation and persuasion) to analyse 
when pursuing health sector reform (figure 1).6 It is 
important to recognise, however, that health system 
actors and the population interact within rapidly 
changing environments that either physically (eg, road 
networks), socially (eg, education and socioeconomic 
status) or politically (eg, institutions) determine health 
promotion and care. These, in turn, play an important 
role in determining quantitative and dynamic relation-
ships between health system components, policy levers 
and the population.11 An example of such relationships 
is the procurement and delivery of medicines, which, 
from manufacturers to clinics, evolve continuously 
over time in response to the population demand and 
behaviour and drug stock-outs, and are characterised 
by ever-changing feedbacks to suppliers, which can 
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Table 1 Possible challenges of and approaches to health system modelling research
Challenge Description Potential approach
Formulation of model  Ź The model should capture the dynamic 
interactions between the main components of 
the health system and acknowledge constraints.
 Ź Deciding on which components and constraints 
to include depends on what is most relevant to 
the problem under study and data availability.
 Ź Assembling all available datasets before model 
conceptualisation enables modellers to recognise 
what should be included in the model.
 Ź Examples of datasets include: household surveys for 
population health and socioeconomic characteristics, 
geographic information systems for facility locations 
and human resource allocations, health management 
information systems for drug stocks and patient 
visits.
Parametrisation of 
model
 Ź The model can consist of many parameters that 
need to be identiied.
 Ź In addition to the dificulty of dealing with a 
large parameter space, some parameters are 
qualitative in nature (eg, skills of workforce, 
quality of education, political feasibility).
 Ź Parameters can be extracted from a plethora of 
datasets from multiple sources such as: Demographic 
and Health Surveys, Multiple Indicator Cluster 
Surveys, Service Provision Assessment, Service 
Availability and Readiness Assessment, National 
Health Accounts, World Development Indicators, 
Global Burden of Disease Study.
 Ź As for qualitative features, numerical values may be 
assigned to different categories of a certain variable 
(eg, for rating workforce skills) and a variety of 
scenario analyses can be conducted.
Validation of model  Ź Multiple distinct datasets should be used to 
validate the model.
 Ź Multiple intermediate indicators and outputs (eg, 
coverage of health services) along with outcomes (eg, 
disease incidence) should be monitored.
Large simulations  Ź The model can consist of many compartments 
and routines depending on both space and 
time (eg, location of health facilities and road 
networks relative to population distribution, drug 
supply chain) which requires the use of large 
simulations.
 Ź High performance computing and parallel 
programming can be used to perform such required 
large simulations.
Presentation of model 
results
 Ź The model can consist of multiple outcomes to 
be evaluated.
 Ź The model should allow a clear comparison of 
impact between HSS interventions.
 Ź Present model indings with the use of dashboards 
displaying all possible outcomes or with aggregating 
outcomes using weights.
 Ź Deine the limits of the impact of HSS interventions 
and the status quo.
Data gaps  Ź A large data repository is preferable to build a 
complete model, yet data gaps are inevitable.
 Ź Once gaps are identiied, data collection can be 
pursued to improve future versions of the model.
be enhanced depending on the organisational and 
financing capacity that is embedded in the broader 
policy environment (eg, national patent policy, regula-
tory capacity of generic drugs).
In this respect, HSM research can use systems 
thinking,12 a qualitative stepping stone towards model-
ling, to represent the health system as a complex 
adaptive system. Using systems thinking will imply 
synthesising the intrinsic features including control 
loops (dynamic interactions resulting from policy 
levers) and feedbacks (nature and quantification of 
these interactions). Drawing from other disciplines 
like operations research, management and behavioural 
sciences and using system dynamics,13 14 discrete-event 
simulations analysing queuing processes15 16 and agent-
based modelling materialising adaptive systems15 17 
sampling from large datasets, we can develop dynamic 
simulation models (both qualitative and quantitative in 
nature) of health systems that are able to predict the 
effect of acting on a given policy lever (figure 1).
For instance, removing fee-for-service for selected 
healthcare services would initially increase population 
demand, modulated by individuals’ quality of care 
perception, which, contingent on external constraints, 
will drive the drug supply and workforce deployment, 
further requiring additional funds and eventually 
leading to adjusting the initial population demand, 
stabilising it at a different level. Evaluating this 
requires the use of a simulation model that includes 
such dynamics and their associated costs and benefits. 
However, HSM research will imply specific challenges 
which analysts will need to address (table 1).
Incorporating the constraints limiting the delivery of health to 
the population
National health systems rely on a range of physical enti-
ties including delivery platforms (eg, hospitals, clinics, 
district public health offices), the arrangement of preven-
tion and treatment services and the deployed workforce 
(eg, doctors, nurses, community health workers).18 
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This physical architecture dictates the interconnections 
between platforms, services, workforce and the popula-
tion, which cannot function in isolation from each other; 
it also defines the limits of the health system capabilities. 
Notably, health services can be interdependent through 
a commonly shared delivery platform in three ways:19 
through the quality of care of an existing platform (eg, 
quality is improved for the whole platform, such as an 
operating room providing a range of services), through 
the specific constraints underpinning an existing plat-
form (eg, limited medical equipment and personnel) 
and through the constitution of new platforms (eg, new 
clinics) jointly bundling these health services. Recog-
nising this, it is clear that the eventual impact of any given 
policy lever will be constrained by the underlying archi-
tecture of the health system including its policy environ-
ment (figure 1).
Importantly, HSM research must describe health 
systems through the types and in-between links of delivery 
platforms, services provided and workforce deployed. 
First, this description involves classifying and quan-
tifying the health system infrastructure (eg, services, 
platforms, facilities), the distribution and allocation 
of human resources (eg, health vs non-health work-
force) and the contextual networks impacting health 
delivery (eg, roads, population locations). Second, it 
suggests that it will be important to measure and assess 
the financial (eg, availability of public vs private funds) 
and leadership/political (eg, civil vs governmental 
stakeholders influencing policymaking and implemen-
tation) dimensions that constrain the implementation 
of HSS interventions.18 For instance, system dynamic 
methods can be used to capture complex systems and 
trade-offs between cure and prevention interventions 
and the impact of adapted policies.20 Politics can also 
serve as a driver of reform and implementation. Thus, 
political analysis and modelling can be useful on their 
own,21 especially to understand and incorporate polit-
ical constraints.
Finally, pursuing such a detailed description of 
health systems amenable to modelling should be tied 
to using multiple sources of data (both health and 
non-health). For example, geographic information 
systems can procure detailed maps of settings including 
buildings, and big data from social media can generate 
behavioural information; linking GPS coordinates of 
roads, villages and facilities and management informa-
tion systems on patient visits and drug stocks can enable 
diagnosis of supply and delivery bottlenecks (table 1).
ConCluSIon
HSM research should model the complex dynamics of 
health systems and ultimately guide a novel economic 
evaluation framework for analysing HSS interventions. 
To achieve this, HSM research can use dynamic math-
ematical models to predict the value for money of HSS 
interventions and policy changes.
The HSS interventions to study would draw from the 
five policy levers detailed by Roberts and colleagues,6 
whose spheres of action and eventual impact would be 
quantitatively determined by the underlying physical 
architecture of the health system and the dynamic inter-
actions between its components. A possible element of 
these analyses could be to anchor health system models 
within an ‘Input–Output’ framework, where the policy 
levers (eg, financing, payment, organisation, regula-
tion, persuasion) include inputs and processes of how 
inputs are used, where health system objectives (eg, 
level and distribution of health, financial risk protec-
tion) are considered outcomes and where all available 
evidence is used to appropriately associate the inputs, 
outputs and outcomes.
Finally, HSM research to identify good value for 
money investments in HSS would have implications for 
the broader global health community. National govern-
ments, donors and the research community would 
need to collect system-wide indicators (eg, quality22 and 
financial risk protection23 indicators) rather than solely 
disease-specific indicators. Rather than single vertical 
programmes, they should also economically evaluate 
HSS programmes, including their costs and impact on 
health, and understanding the role of the health system 
components in that impact.
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